Triangle211At-BC8-B10 Before Stem Cell… (NCT03670966)
211At-BC8-B10 Before Stem Cell Transplant trial for High-Risk Acute Leukemia or Myelodysplastic Syndrome (NCT03670966). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for relapsed or refractory high risk acute leukemia or myelodysplastic syndrome, in adults 18 to 75.
The idea: a radioactive agent linked to an antibody, called 211At BC8 B10, is given before a donor stem cell transplant, along with chemotherapy and total body irradiation.
This phase 1 and 2 study plans 30 patients and looks first at side effects and the best dose. The main measure is dose limiting toxicity. At Fred Hutchinson Cancer Center in Seattle, Phuong Vo leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.